导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.19% | 1111/4773 |
| 近一周 | -2.38% | 2014/5462 |
| 近一月 | -4.67% | 2640/5421 |
| 近一季 | -7.71% | 2504/5209 |
| 近半年 | -2.90% | 2060/4920 |
| 近一年 | 9.58% | 1080/4366 |
| 近两年 | 77.22% | 848/2954 |
| 近三年 | 41.58% | 684/2253 |
| 成立以来 | 332.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.53% 1515/4961 |
20.38% 1231/5312 |
- - |
- - |
| 2025 | 30.30% 1336/4813 |
5.41% 782/3635 |
1.96% 1991/4076 |
19.39% 2152/4524 |
1.55% 1339/4813 |
| 2024 | 10.45% 1409/3463 |
-1.23% 1200/2808 |
-3.00% 1286/3014 |
11.00% 2569/3129 |
3.86% 759/3463 |
| 2023 | -9.58% 1193/2656 |
4.93% 855/2280 |
-3.70% 873/2385 |
-4.69% 1202/2515 |
-6.12% 1632/2655 |
| 2022 | -19.27% 826/2207 |
-10.87% 444/1919 |
4.81% 973/2016 |
-11.88% 603/2113 |
-1.92% 1757/2208 |
| 2021 | 18.21% 214/1822 |
2.81% 210/1255 |
10.95% 416/1330 |
4.70% 326/1466 |
-1.02% 1298/1822 |
| 2020 | 34.99% 427/1250 |
-1.38% 217/1028 |
17.14% 389/1067 |
11.87% 421/1164 |
4.46% 839/1184 |
| 2019 | 38.17% 315/1092 |
32.29% 177/754 |
-9.60% 672/804 |
7.00% 106/850 |
7.98% 370/918 |
| 2018 | -27.86% 428/834 |
- - |
- - |
- - |
-11.92% 383/691 |
| 2017 | 11.92% 289/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.61% 225/605 |
- - |
- - |
- - |
- - |
| 2015 | 57.66% 9/575 |
- - |
- - |
- - |
- - |
| 2014 | 32.23% 156/237 |
- - |
- - |
- - |
- - |
| 2013 | 14.57% 30/186 |
- - |
- - |
- - |
- - |
| 2012 | -1.40% 130/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 宏利500指数增强(LOF) VS. 长安沪深300非周期A(740101) |